Logo image of ACTU

ACTUATE THERAPEUTICS INC (ACTU) Stock Fundamental Analysis

USA - NASDAQ:ACTU - US0050831009 - Common Stock

7.46 USD
-0.02 (-0.27%)
Last: 10/20/2025, 2:48:50 PM
Fundamental Rating

0

Overall ACTU gets a fundamental rating of 0 out of 10. We evaluated ACTU against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of ACTU have multiple concerns. ACTU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ACTU had negative earnings in the past year.
In the past year ACTU has reported a negative cash flow from operations.
ACTU Yearly Net Income VS EBIT VS OCF VS FCFACTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

ACTU's Return On Assets of -354.20% is on the low side compared to the rest of the industry. ACTU is outperformed by 94.57% of its industry peers.
Industry RankSector Rank
ROA -354.2%
ROE N/A
ROIC N/A
ROA(3y)-405.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACTU Yearly ROA, ROE, ROICACTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -5K -10K -15K -20K -25K

1.3 Margins

ACTU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACTU Yearly Profit, Operating, Gross MarginsACTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for ACTU has been increased compared to 1 year ago.
ACTU has a better debt/assets ratio than last year.
ACTU Yearly Shares OutstandingACTU Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
ACTU Yearly Total Debt VS Total AssetsACTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -30.30, we must say that ACTU is in the distress zone and has some risk of bankruptcy.
ACTU has a worse Altman-Z score (-30.30) than 89.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -30.3
ROIC/WACCN/A
WACCN/A
ACTU Yearly LT Debt VS Equity VS FCFACTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

ACTU has a Current Ratio of 0.73. This is a bad value and indicates that ACTU is not financially healthy enough and could expect problems in meeting its short term obligations.
ACTU's Current ratio of 0.73 is on the low side compared to the rest of the industry. ACTU is outperformed by 90.45% of its industry peers.
A Quick Ratio of 0.73 indicates that ACTU may have some problems paying its short term obligations.
With a Quick ratio value of 0.73, ACTU is not doing good in the industry: 89.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.73
Quick Ratio 0.73
ACTU Yearly Current Assets VS Current LiabilitesACTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ACTU have decreased by -8.53% in the last year.
EPS 1Y (TTM)-8.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACTU is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.45%
EPS Next 2Y26.29%
EPS Next 3Y14.37%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACTU Yearly Revenue VS EstimatesACTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 1M 2M 3M 4M
ACTU Yearly EPS VS EstimatesACTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACTU. In the last year negative earnings were reported.
Also next year ACTU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACTU Price Earnings VS Forward Price EarningsACTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACTU Per share dataACTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ACTU's earnings are expected to grow with 14.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.29%
EPS Next 3Y14.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACTU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACTUATE THERAPEUTICS INC

NASDAQ:ACTU (10/20/2025, 2:48:50 PM)

7.46

-0.02 (-0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-13 2025-11-13
Inst Owners48.96%
Inst Owner Change0%
Ins Owners4.11%
Ins Owner Change0%
Market Cap170.98M
Analysts82
Price Target27.29 (265.82%)
Short Float %2.95%
Short Ratio7.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.04%
Min EPS beat(2)-3.43%
Max EPS beat(2)3.52%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.5%
EPS NY rev (1m)-1.91%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-1.31
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -354.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-405.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.73
Quick Ratio 0.73
Altman-Z -30.3
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.94%
EPS Next Y63.45%
EPS Next 2Y26.29%
EPS Next 3Y14.37%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.01%
OCF growth 3YN/A
OCF growth 5YN/A